Agreed, now we have Bristol, Astra and Merck collaborating with ADXS for potential combination licensing deals. This is positive. I still think we will see a monetary deal for AXAL in Europe soon given the company is about to apply for Europe monotherapy approval for cervical cancer but doesn't have a commercialization plan in place yet.